sur GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Schedules Annual General Meeting for May 2026
GenSight Biologics, a biopharma firm specializing in gene therapies, has set its Annual General Meeting for May 19, 2026. The meeting will occur at 2:00 pm CEST at the company's headquarters in Paris, with an option for shareholders to join through a live webcast.
The agenda and draft resolutions have already been published in the French BALO. A subsequent notice confirming the meeting details will appear in a legal gazette by May 4, 2026. Interested shareholders can access preparatory documents on the company's website or request them via email.
The company emphasizes the availability of these documents in compliance with French legal codes. Shareholders may request additional details by contacting investor relations, provided they validate their shareholder status.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de GENSIGHT BIOLOGICS S.A.